On April 1, 2026, the FDA approved orforglipron, marketed as Foundayo, for adults with obesity or who are overweight with a weight-related medical condition. It is the first GLP-1 receptor agonist pill that can be taken once daily at any time, without the fasting or water restrictions that apply to the only previous oral GLP-1 option.

An Important Distinction: It's Not a Peptide

This site covers peptide therapies, so it's worth being precise here: orforglipron is not a peptide. Existing GLP-1 drugs like semaglutide and tirzepatide are peptides, chains of amino acids that are easily broken down by digestive enzymes, which is exactly why they're normally given by injection. Orforglipron is a small, non-peptide molecule engineered specifically to activate the same GLP-1 receptor while surviving the digestive tract intact. That chemistry is the reason it can be swallowed as an ordinary tablet without the strict administration rules that oral peptide drugs require.

Why the "No Restrictions" Detail Matters

The only previously approved oral GLP-1 medicine, oral semaglutide, is still a peptide, and getting a meaningful dose absorbed requires taking it on an empty stomach with a small sip of water, then waiting at least 30 minutes before eating, drinking, or taking other medications. Because orforglipron isn't a peptide and doesn't rely on the same absorption workaround, Lilly's approved labeling allows it to be taken any time of day, with or without food.

What the Approval Covers

Foundayo is approved as an adjunct to a reduced-calorie diet and increased physical activity, available in six tablet strengths from 0.8 mg up to 17.2 mg, taken once daily. In the pivotal ATTAIN-1 trial, participants who completed treatment at the highest studied dose lost an average of 27.3 pounds (about 12.4% of body weight), compared with 2.2 pounds in the placebo group; results were more modest when everyone enrolled was counted, regardless of whether they completed the trial.

The approval came through the FDA's National Priority Voucher Program, a pathway intended to speed review of medicines the agency considers a priority, and orforglipron was the first new molecular entity cleared under that program.

Safety Information

Foundayo's labeling carries a boxed warning about the risk of thyroid C-cell tumors, including thyroid cancer, based on findings in animal studies with this drug class; it is contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Other labeled risks include pancreatitis, severe gastrointestinal problems, dehydration, and allergic reactions, and the most commonly reported side effects in trials were nausea, constipation, diarrhea, and vomiting, side effects broadly similar to those seen with injectable GLP-1 drugs.

The Bottom Line

Orforglipron's approval is a genuine pharmacological milestone: an oral GLP-1 therapy that sidesteps peptide degradation in the gut entirely, rather than working around it. It does not change the safety profile associated with the GLP-1 drug class generally, and it is a prescription medicine with the same category of serious risks and monitoring needs as its injectable counterparts. Anyone considering it should discuss their full medical history, including thyroid and pancreatic risk factors, with a licensed physician.